# OnCo record hcc-intermediate (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/hcc-intermediate/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "hcc-intermediate" ;
  schema:name "Intermediate hepatocellular carcinoma (BCLC B)"@en ;
  schema:alternateName "Intermediate-stage HCC"@en, "Multinodular HCC"@en, "TACE-eligible hepatocellular carcinoma"@en, "BCLC B"@en ;
  schema:description "Intermediate hepatocellular carcinoma is several tumours inside a working liver, too many to cut out but with no spread beyond it. The standard treatment for two decades has been chemoembolisation through the hepatic artery, and trials now show that adding immunotherapy and anti-angiogenic drugs to it delays progression."@en ;
  schema:url <https://onco.cc/cancers/hcc-intermediate/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Transcatheter_arterial_chemoembolization> ;
  schema:citation <https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02551-0/abstract>, <https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract>, <https://pubmed.ncbi.nlm.nih.gov/34801630/>, <https://en.wikipedia.org/wiki/Transcatheter_arterial_chemoembolization> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/trials/emerald-3/>, <https://onco.cc/pairings/tace-plus-systemic/>, <https://onco.cc/technologies/radioembolisation-tare/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/lenvatinib/> ;
  onco:standardOfCare <https://onco.cc/technologies/tace/>, <https://onco.cc/terms/tace-term/>, <https://onco.cc/technologies/radioembolisation-tare/>, <https://onco.cc/terms/bclc-staging/>, <https://onco.cc/trials/emerald-1/>, <https://onco.cc/trials/leap-012/>, <https://onco.cc/trials/emerald-3/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/pairings/tace-plus-systemic/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/trials/imbrave150/>, <https://onco.cc/trials/himalaya/>, <https://onco.cc/technologies/liver-transplant-oncology/>, <https://onco.cc/terms/bridging-therapy/>, <https://onco.cc/technologies/tace/> .